Most Likely Indication for Glenohumeral Joint Injection
The most likely indication for glenohumeral joint injection is glenohumeral osteoarthritis, which represents one of the most common etiologies of shoulder pain requiring intra-articular treatment. 1
Primary Indications
Glenohumeral Osteoarthritis
Glenohumeral osteoarthritis is the predominant indication for intra-articular injection, particularly in patients seeking non-surgical management. 1 The condition is more common in women and increases with age, making the shoulder the third most common joint (after knee and hip) requiring intervention. Injectable treatments for GHOA include:
- Corticosteroids: Widely used in clinical practice for shoulder pain, though evidence specifically for GHOA remains limited 1
- Viscosupplementation: Represents a weak treatment option (Grade C recommendation) for GHOA management 1
- Hyaluronic acid preparations: Studies demonstrate significant pain reduction and functional improvement lasting up to 6 months 2, 3
Adhesive Capsulitis (Frozen Shoulder)
This is the second most common indication for glenohumeral injection. Early-stage adhesive capsulitis (Stages 1-2) responds particularly well to intra-articular corticosteroid injection, with the inflammatory process providing a clear rationale for intervention before capsular fibrosis develops. 4, 5
Key clinical points:
- Stage 1 patients achieve recovery criteria in 2-6 weeks (100% for forward flexion and internal rotation)
- Stage 2 patients require 7-10 weeks (62% for forward flexion, 72% for internal rotation)
- Earlier intervention yields superior outcomes 4
Rheumatoid Arthritis
Glenohumeral joint involvement in rheumatoid arthritis represents another established indication for intra-articular injection. 5
Diagnostic Considerations
When Glenohumeral Injection is Appropriate:
- Concentric glenohumeral joint osteoarthritis with pain on movement and limited function 2
- Inflammatory shoulder conditions not responding to NSAIDs, physical therapy, or activity modification 5
- Early adhesive capsulitis (within weeks of symptom onset for optimal results) 4
Technical Approach Selection:
The injection approach should target the predominant pathology:
- Rotator interval approach: Preferentially addresses anterior structures and biceps tendon sheath pathology 6
- Posterior glenohumeral approach: Most consistently infiltrates posterior capsule but provides inconsistent anterior coverage 6
- Dual-target technique: Combines rotator interval and subdeltoid bursal injection for combined pathology 6, 7
Important Clinical Caveats
Ultrasound guidance improves accuracy (63-100%) compared to landmark-guided injections (40-76%), though clinical efficacy outcomes remain similar between techniques. 8 However, ultrasound-guided injections may provide faster pain relief in the early period. 9
For impingement syndrome with mild stiffness, glenohumeral injections demonstrate earlier gains in range of motion (within 3 weeks) compared to subacromial injections, though outcomes equalize by 3 months. 9
The overall complication rate for glenohumeral injections is 7.2%, with a surgery rate of 3.2% for persistent symptoms. 3